Background: Serum phosphorus is associated with cardiovascular disease (CVD) in the general population, but may not comprehensively reflect phosphorus homeostasis. Whether urine phosphorus-creatinine ratio (a marker of intestinal absorption) or urine fractional excretion of phosphorus (FE Pi ; a marker of urinary phosphorus handling) is associated with risk of mortality or CVD is uncertain.
I
n vitro studies have shown that higher extracellular phosphorus concentrations are an integral trigger for vascular smooth muscle cells becoming osteoblastlike cells and for calcium then being deposited in the vascular wall. 1 Elevated serum phosphorus concentrations in patients with end-stage renal disease confer higher risks of coronary artery calcification and allcause and cardiovascular disease (CVD) mortality. [2] [3] [4] Similar associations have been described in persons with normal or near-normal kidney function, for whom higher phosphorus concentrations have been linked to arterial calcification [5] [6] [7] and mortality. 8, 9 The association between phosphorus concentrations and CVD events in the general population is less certain because some, [9] [10] [11] but not all, studies 8, 12, 13 have reported such associations.
These findings have led to interest about whether lowering serum phosphorus levels may decrease CVD event rates in the general population. In end-stage renal disease populations, oral phosphorus binders frequently are used to lower serum phosphorus concentrations by diminishing intestinal absorption. However, in prior studies of patients with chronic kidney disease (CKD), oral phosphorus binders failed to meaningfully lower serum phosphorus concentrations despite decreasing 24-hour urinary phosphorus excretion (an indicator of gastrointestinal phosphorus absorption) and the fractional excretion of phosphorus (FE Pi , an indicator of renal phosphorus excretion relative to the concurrent serum phosphorus concentrations).
14-16 Some have suggested that decreases in urine phosphorus or FE Pi may be useful surrogates for phosphorus-lowering interventions even if serum phosphorus concentrations are unchanged because urine phosphorus excretion and FE Pi nonetheless may mark improved phosphorus homeostasis. 16, 17 To be useful as surrogates, these urine measures should themselves be associated with all-cause and CVD mortality. To our knowledge, these associations have not been tested, and their relative strengths of association with outcomes have not been compared with those of serum phosphorus concentrations.
Our objective was to evaluate the relationships between urine phosphorus indexed to urine creatinine (urinary phosphorus-creatinine ratio, an indicator of intestinal phosphorus absorption 16, 18 ) and FE Pi with all-cause and CVD mortality in community-living older men who participated in the Osteoporotic Fractures in Men (MrOS) Study. We began by evaluating serum phosphorus and subsequently compared the strengths of association of urine phosphorus-creatinine ratio and FE Pi . We hypothesized that high urine phosphorus-creatinine ratio and high FE Pi would be associated with all-cause and CVD death, and that these associations would be stronger than those of serum phosphorus level.
METHODS

Participants
The MrOS Study is a prospective observational study designed to determine risk factors for osteoporosis and fractures in men 65 years and older. Between March 2000 and April 2002, a total of 5,994 men were recruited from 6 clinical sites in the United States: Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Pittsburgh, PA; Portland, OR; and San Diego, CA. Study design and recruitment techniques have been described in detail elsewhere. 19, 20 Institutional review boards at each center approved the study protocol.
A random sample of 1,582 participants was chosen for additional serum and urine measurements, including urine phosphorus. From these individuals, we excluded those with missing baseline urine phosphorus measurements (n ϭ 7), serum phosphorus measurements (n ϭ 94), and covariate data (n ϭ 102) and those without follow-up information after baseline (n ϭ 54), resulting in a final analytic sample of 1,325 participants. Those excluded from the analysis were older, were less likely to be white, and had higher serum phosphorus levels, whereas urine phosphorus-creatinine ratio, FE Pi , and estimated glomerular filtration rate (eGFR) values were similar (Table S1 , provided as online supplementary material).
The Outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study, an ancillary study of outcomes related to sleep disorders, was initiated during the follow-up period (mean, 3.4 years after baseline examination). A total of 3,135 men without known sleep apnea participated, and 2,883 provided urine samples, which were assayed for urine phosphorus and creatinine. Of these participants, 639 were part of our randomly selected sample at baseline, and we evaluated the intraclass correlation of urine phosphorus-creatinine ratio over time in this subgroup.
Measurements
Serum and Urine Phosphorus
Serum and urine samples were collected after an overnight fast. Phosphorus and creatinine were measured using a standard clinical automated analyzer. The lower limits of detection for serum and urine phosphorus were 0.3 and 3.4 mg/dL, and interassay coefficients of variation (CVs) were Ͻ2.4% and Ͻ1.5%, respectively. Serum creatinine was measured using a Roche COBAS Integra 800 analyzer (Roche Diagnostics) using an enzymatic method calibrated with materials assayed by isotope-dilution mass spectrometry. Interassay CV was 5.3%. eGFR was calculated using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation. 21 Urine creatinine measurements were made using the same clinical automated analyzer. The lower limit of detection was 4.2 mg/dL, and CV was 2.7%.
Urine phosphorus was divided by urine creatinine to calculate urine phosphorus-creatinine ratio in milligrams per milligram. FE Pi (percentage) was calculated as follows: [urine phosphorus (mg/dL)/serum phosphorus (mg/dL)] ϫ [serum creatinine (mg/dL)/ urine creatinine (mg/dL)] ϫ 100. 
All-Cause and Cardiovascular Mortality
Other Measurements
Age and race were self-reported. At the baseline visit, interviewers completed a medication inventory of prescribed medications taken in the last 30 days. All medications were stored in an electronic medications inventory database and each medication was matched to its ingredient(s) based on the Iowa Drug Information Service Drug Vocabulary. 22 Systolic blood pressure was measured twice in the right arm using a conventional mercury sphygmomanometer, and the average was used in analysis. Height was measured twice using a Harpenden Stadiometer (Holtain Ltd), and results were averaged. Weight was measured using either a balance beam or digital scale. Body mass index (BMI) was calculated (kg/m 2 ). Diabetes was defined as fasting blood glucose level Ն126 mg/dL, self-reported history of physician's diagnosis, or use of oral hypoglycemic medications or insulin. Smoking was Am J Kidney Dis. 2013;xx(x):xxxclassified as current, former, or never. History of congestive heart failure, myocardial infarction, angina, or stroke defined prevalent CVD.
Decreased eGFR was defined as eGFR Ͻ60 mL/min/1.73 m 2 . Urine albumin was measured on a standard clinical automated analyzer with a lower limit of detection of 0.3 mg/dL and an interassay CV Ͻ3.6%. When urine albumin excretion was less than the detectable limit of 0.3 mg/dL, a value of 0.29 mg/dL was assigned. Urine albumin-creatinine ratio (ACR) was calculated (milligrams per gram), and microalbuminuria was defined as urine ACR Ͼ30 mg/g.
23
Statistical Analysis
Participant baseline characteristics were compared across quartiles of serum phosphorus, urine phosphorus-creatinine ratio, and FE Pi . We used linear regression to evaluate the P value for trend across quartiles for continuous variables and 2 for categorical variables. Pearson correlation evaluated correlations among serum phosphorus level, urine phosphorus-creatinine ratio, FE Pi , and eGFR at the baseline study visit. For the subset of participants with urine phosphorus measurements at the sleep study subset, we calculated intraclass correlations.
Cox proportional hazards regression was used to evaluate the association between serum phosphorus level, urine phosphoruscreatinine ratio, and FE Pi and all-cause and CVD mortality. To allow for comparisons, each predictor variable was evaluated by quartiles. Sequential models were developed. The initial model was adjusted for age and race. The second model additionally adjusted for eGFR and microalbuminuria. The third model additionally adjusted for prevalent CVD and traditional CVD risk factors (diabetes, systolic blood pressure, antihypertensive medication use, smoking status, BMI, total cholesterol level, high-density lipoprotein cholesterol level, and lipid medication use). Last, we tested for effect modification in the associations of each predictor with each outcome by eGFR status (Ͻ or Ն a threshold value of 60 mL/min/1.73 m 2 ) in the fully adjusted model. When statistically significant interactions were detected, associations were evaluated within strata of eGFR. Proportional hazards assumptions were evaluated by visually checking log-minus-log plots and plots of Schoenfeld residuals versus survival time for the association of each of the 3 predictor variables with both mortality and CVD death. We found no evidence of violations.
Analyses were conducted using Stata SE, version 11.0 (StataCorp LP), and P Ͻ0.05 was considered statistically significant for all analyses including interaction terms.
RESULTS
For the 1,325 study participants, mean age was 74 Ϯ 6 (SD) years and 91% were white. Mean eGFR was 75 Ϯ 16 mL/min/1.73 m 2 , and 223 participants (17%) had eGFR Ͻ60 mL/min/1.73 m 2 . During a median of 9.3 (interquartile range [IQR], 8.7-9.9) years of follow-up, there were 364 deaths. Of these, 120 were CVD deaths. Mean serum phosphorus concentration was 3.2 Ϯ 0.4 mg/dL, urine phosphoruscreatinine ratio was 0.45 Ϯ 0.17 mg/mg, and FE Pi was 14% Ϯ 6%.
Baseline characteristics of study participants by quartiles of serum phosphorus level, urine phosphoruscreatinine ratio, and FE Pi are listed in Table 1 . Compared with the lowest serum phosphorus quartile, those with higher concentrations had lower eGFR, had a greater prevalence of CVD and diabetes, and were more likely to be taking blood pressure medications. They also had a higher BMI and serum highdensity lipoprotein cholesterol level and were more likely to be taking lipid medications. Participants with higher urine phosphorus-creatinine ratios were older and had higher urine ACRs, greater prevalence of CVD and diabetes, greater tobacco use, and higher BMI. Participants with higher FE Pi were older and had a lower eGFR, higher urine ACR, greater prevalence of CVD and diabetes, and higher systolic blood pressure; more frequently took blood pressure medication; and had a higher BMI, lower total cholesterol level, and lower serum high-density lipoprotein cholesterol level. Table 2 shows the correlations of the 3 markers of phosphorus homeostasis with one another and with eGFR. The strongest correlation was between urine phosphorus-creatinine ratio and FE Pi (r ϭ 0.75). FE Pi was the marker most strongly and inversely correlated with eGFR. In the subset of 639 participants who underwent repeated urine phosphorus-creatinine ratio measurements a mean of 3.4 (IQR, 3.0-3.7) years later, the intraclass correlation was 0.28. Serum phosphorus level was not available at the follow-up visit; thus, the test-retest correlation of serum phosphorus level and FE Pi is unknown. Table 3 lists hazard ratios (HRs) for all-cause mortality by quartiles of each marker of phosphorus homeostasis. Compared with the lowest serum phosphorus quartile, individuals in test quartiles 2 and 3 had similar risks of all-cause mortality, whereas those in the highest quartile had a 72% greater risk of death in an age-and race-adjusted model. After adjustment for eGFR, microalbuminuria, prevalent CVD, and traditional CVD risk factors, this association essentially was unaltered. Figure 1 shows the nature of the relationship between phosphorus levels and all-cause death across quartiles, with the highest quartile divided into 3 groups (serum phosphorus of 3.6-3.7, 3.8-3.9, and Ն4.0 mg/dL) to explore the nature of the relationship of phosphorus levels with death in greater detail. Although allcause mortality rates were somewhat higher in those with serum phosphorus levels of 3.6-3.9 mg/dL (4%-5%), the rate was particularly high for those with levels Ն4.0 mg/dL (6%).
The association of urine phosphorus-creatinine ratios with death was modest compared to that of serum phosphorus levels (Table 3) . Adjustment for eGFR and urine ACR had little influence on the association. However, when the association was adjusted additionally for traditional CVD risk factors and prevalent CVD, it was rendered not significant. Results were similar when we evaluated urine phosphorus concen- trations without indexing to creatinine (data not shown). Results also were similar when evaluating FE Pi . In age-and race-adjusted models, the highest quartile of FE Pi was associated with a 28% higher risk of mortality. However, this association was attenuated after adjustment for kidney function and was attenuated further with adjustment for CVD risk factors and prevalent CVD. Although the associations of serum phosphorus levels and urine phosphorus-creatinine ratios with all-cause death were similar in persons with or without decreased GFR (interaction P ϭ 0.8 and P ϭ 0.6, respectively), the association of FE Pi with all-cause mortality differed by eGFR status (P for interaction ϭ 0.05). In persons with eGFR Ͻ60 mL/min/1.73 m 2 , each 1-SD greater FE Pi was associated with a 19% (95% confidence interval [CI], Ϫ1% to 43%; P ϭ 0.07) higher risk of all-cause mortality in the final model, whereas no association was observed in those with higher eGFR (HR, 1.02; 95% CI, 0.88-1.18; P ϭ 0.8). However, given the strong inverse correlation between FE Pi and eGFR, we hypothesized that the association within the decreased eGFR subset might reflect differing severity of CKD. After adjustment for eGFR within the decreased eGFR strata, the association of FE Pi (per 1-SD higher) with all-cause mortality was attenuated from 19% to 1% (P ϭ 0.9). Figure 2 shows annual CVD death rates across categories of serum phosphorus. Again, there was a slightly greater risk of CVD death with higher phosphorus categories, but the association was most dramatic in the Ն4.0-mg/dL group. In the fully adjusted model, the highest quartile of serum phosphorus was associated with a 56% higher risk of CVD death compared to the lowest quartile (Table 4 ). In contrast, the associations of urine phosphorus-creatinine ratio and FE Pi quartiles with CVD death were modest, and neither was associated with CVD death in the fully adjusted model. We again observed that the association of FE Pi with CVD mortality differed by eGFR status (P for interaction ϭ 0.02); however, after adjustment for eGFR within the strata with decreased eGFR, this association was attenuated and no longer statistically significant (P ϭ 0.2).
DISCUSSION
We hypothesized that urine phosphorus-creatinine ratio might more accurately mark total phosphorus intake and systemic exposure compared with the fasting morning serum phosphorus concentration. We also hypothesized that greater renal excretion of phosphorus (marked by high FE Pi ) might be associated with CVD. If associated with outcomes, these measures might serve as useful surrogate markers for interventions aimed at improving phosphorus balance to decrease CVD, even if they do not change serum phosphorus concentrations. However, we found that neither of these markers was associated with all-cause or CVD mortality in this population of communityliving older men. These findings confirm the importance of serum phosphorus level as a prognostic marker and as a potential target for therapies aimed at improving phosphorus balance to decrease CVD death. However, our findings do not support a strategy aimed at single urinary measurements of phosphorus homeostasis for the same purpose.
In contrast to FE Pi and urine phosphorus-creatinine ratio, we observed a relatively strong association between serum phosphorus concentration and allcause and CVD mortality. This association was unaltered after adjustment for demographics, traditional CVD risk factors, prevalent CVD, and kidney function and also was evident in the subgroup of individu- als with eGFR Ն60 mL/min/1.73 m 2 . Prior studies evaluating this association in the general population have yielded conflicting results. Two studies reported associations between serum phosphorus level and CVD mortality, 10,11 whereas 4 others did not. 6, 12, 13, 24 The reasons for these disparate findings are uncertain, but sex distribution in the study samples is one possible explanation. In the Atherosclerosis Risk in Communities (ARIC) Study (mean age, 54 years), higher phosphorus level was associated with mortality in men, but not women. 11 In another study, an association between serum phosphorus level and left ventricular mass was observed in men, but not women. 25 A third study of an all-female cohort found no association of serum phosphorus level with CVD mortality. 13 Estrogen has phosphaturic properties, 26 leading women to have higher serum phosphorus concentrations after menopause. 27 Thus, serum phosphorus concentrations in women may partially reflect menopausal status and estrogen concentrations, which may confound the relationship of phosphorus level with CVD in women. Future studies of community-living cohorts of both sexes are required to determine whether the associations observed here extend to women.
In patients with end-stage renal disease, oral phosphorus binders decrease serum phosphorus levels. Studies of patients with CKD have shown that oral phosphorus binders have little or no effect on serum phosphorus concentrations.
14-16, 18 We have shown that once-daily niacin lowers serum phosphorus concentrations by ϳ1 SD (ϳ0.4 mg/dL) in patients with CKD, 28 and similar findings have been reported in patients with normal kidney function. 29 It is unclear whether niacin improves CVD risk in the general population 30, 31 and whether lowering serum phosphorus level is part of the mechanism.
To our knowledge, only one prior study has evaluated the association of FE Pi with all-cause mortality. 32 The authors evaluated a large cohort of patients with moderate to severe CKD and observed no association with all-cause mortality in fully adjusted models. While we observed that high FE Pi was associated with all-cause and CVD mortality in the subset of patients with eGFR Ͻ60 mL/min/1.73 m 2 , this association was attenuated when adjusted for level of eGFR. Because eGFR and FE Pi are strongly inversely correlated, we believe that the association observed in this subgroup was confounded by the severity of CKD within this subgroup; those who had the highest FE Pi also had the lowest eGFR and the highest death risk. Thus, high FE Pi appears to be marking CKD severity, and we do not believe it is associated independently with all-cause or CVD death. To our knowledge, this is the first study to evaluate the association of urine phosphorus-creatinine ratio with all-cause or CVD mortality in any setting. The urine phosphorus-creatinine ratio indicates the amount of phosphorus that is systemically absorbed from the intestinal tract and excreted into the urine when patients are in steady state. Therefore, investigating this marker provides novel insights into the relationship between dietary phosphorus absorption and CVD and all-cause death. Others have suggested that greater dietary phosphorus intake may be one factor leading to higher serum phosphorus concentrations and adverse health outcomes. 33 We did not observe a statistically significant association between urine phosphoruscreatinine ratio and either all-cause or CVD death in fully adjusted models. It is possible that the urine phosphorus-creatinine ratio measured on spot speci- mens does not accurately reflect dietary phosphorus consumption over longer periods. 34, 35 In a subset of the cohort that had urine phosphorus-creatinine ratio measured twice, we found that the intraclass correlation was modest (r ϭ 0.28). Additionally, prior studies suggest that differences in urine phosphorus excretion are more pronounced later in the day. 34, 35 If so, this may have biased our association of urine phosphoruscreatinine ratio with outcomes toward the null. Future studies with larger sample sizes and repeated measurements of urine phosphorus-creatinine ratio are required to confirm or refute our findings.
Strengths of this study include its evaluation of a well-characterized cohort of community-dwelling individuals with a range of kidney function from normal to moderately decreased eGFR. Few large studies have measured urine phosphorus concentrations, providing us the unique opportunity to examine these associations. The study also has important limitations. As addressed, serum and urine samples were obtained in the morning after an overnight fast. The correlation of spot urine phosphorus-creatinine ratio and FE Pi with 24-hour measures is uncertain. Whether repeated measurements over time or use of 24-hour urine measurements may lead to different results is unknown. Participants were all male, older, and predominantly white and few had advanced CKD. With the exception of urine phosphorus-creatinine ratio, measurements were made at a single time. Urine phosphorus-creatinine ratio was measured repeatedly in a subset, but the subset was chosen based on the absence of sleep apnea.
In conclusion, higher fasting morning serum phosphorus levels were associated more strongly with all-cause and CVD death than fasting morning urine phosphorus-creatinine ratio or FE Pi in communityliving older men. If confirmed, studies aiming to improve phosphorus balance to improve CVD events should focus on lowering serum phosphorus levels rather than urine phosphorus-creatinine ratio or FE Pi . Although the urinary measurements may provide useful information about therapies altering intestinal absorption or urine phosphorus handling, their associations with CVD and death appear weaker or absent. Additional studies are necessary to investigate the most effective therapies to reduce serum phosphorus levels in the general population and determine whether such changes translate into meaningful improvements in length and quality of life. AG18197, U01 AG027810, and UL1 RR024140). Dr Dominguez was supported by a training grant from the National Heart, Lung and Blood Institute (NHLBI; T32 HL007261). Drs Laughlin, Barrett-Connor, and Ix were supported by a grant from the NHLBI (R01HL096851). Additional support was provided by the Sandra Daugherty Foundation. This material is the result of work supported with resources of the Veterans Affairs San Diego Healthcare System. Financial Disclosure: The authors declare that they have no other relevant financial interests. 
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